LMM M&A Market Snapshot — June 17, 2026

Every week I track what buyers are paying in the lower middle market. Not what the headlines say. Not theoretical multiples from pitch decks. Real closed transactions with sources. Here is what the market looks like for the week of June 17, 2026.

Vitamins and Supplements: Buyers Are Paying a Premium and Here Is Why

The supplement market is the outlier story of Q1 and Q2 2026. While the broader consumer M&A sector has contracted 34.7% year over year, supplement deal volume is up. Strategic buyers represent 61% of transactions YTD 2026. PE financial sponsors just hit 14 supplement transactions year to date after a prior year slowdown.

The sector average sits at 10.7x EV/EBITDA for 2024 through YTD 2025. The broader consumer industry comparison is 9.7x. That one-point premium is not random. It reflects structural demand factors that discretionary consumer categories do not share.

(Source: Capstone Partners Vitamins and Supplements M&A Update, June 2026)

What Is Moving Right Now

Four deal dynamics define this market right now:

Women's health supplements are the hottest single category. Elevated premiums are going to brands with subscription or loyalty models in the women's health space. This is where strategic buyers are willing to pay above the sector average. If your brand sits here, you have more buyer options and more pricing power than you may realize.

Strategic buyers are filling portfolio gaps. CPG majors and media or wellness companies are acquiring DTC brands with differentiated formulations and proven consumer loyalty. The logic is straightforward: they can acquire a loyal consumer base and a formulation IP faster than building it, and the M&A market in supplements makes that math work at 10x plus.

Supplement CDMOs are a PE target. Contract manufacturing is its own roll-up thesis right now. The Riverside Company acquired Western Botanicals (Wb Blends), a CDMO founded in 1996 with a 140,000 square foot facility, via BGL. PE is building platforms around supplement manufacturing infrastructure. If you run a CDMO with meaningful capacity, PE sponsors are actively looking.

Personalized nutrition platforms are attracting technology buyers. Herbalife acquired Bioniq, a personalized supplement platform, for $55 million, expected to close Q2 2026. The technology-enabled health angle is pulling in buyers outside the traditional supplement acquirer set.

The Notable Deals This Quarter

The Q1 2026 deal log shows the range of buyer profiles now active in this space:

Danone acquired Huel for $1.2 billion. Functional nutrition at scale, Q1 2026. This is the strategic CPG thesis: buy the brand, the consumer relationship, and the formulation IP rather than build it.

Hindustan Unilever acquired OZiva for $90 million in February 2026. Women's health supplement brand. The premium went directly to the brand's positioning in a high-demand subsegment.

Herbalife acquired Bioniq for $55 million. Personalized supplement platform with technology-enabled health infrastructure. Closing Q2 2026.

Monterey Bay Herb Co. acquired NP Nutra. Ingredient supplier consolidation, adding 1,000 or more botanical SKUs. Strategic supply chain play.

The Riverside Company acquired Western Botanicals. CDMO roll-up. PE platform formation at the manufacturing level, not the brand level.

(Source: NutraIngredients Q1 2026 M&A Roundup)

Five deal profiles. Five different buyer types. That is the point. When a category has strategic buyers, PE platforms, ingredient roll-ups, CPG majors, and technology companies all actively acquiring at the same time, a competitive process does not have to manufacture tension. It already exists in the market.

SaaS / B2B Software: The Profitability Story Continues

Bootstrapped SaaS median holds at 4.8x ARR. LMM all-industry EBITDA sits at 7.2x per GF Data Q1 2026. PE drove 57% of Q1 2026 SaaS deals.

The structural shift from EV/Revenue to EV/EBITDA as the primary metric in SaaS valuations is not reversing. If you run a profitable B2B SaaS business, that shift is in your favor. Buyers are underwriting what a business earns, not what it bills. Clean cap table, strong retention, and EBITDA margins above 20% are where PE sponsors are competing.

No new comparable deal data was available this week for the SaaS segment. Multiple ranges are consistent with the prior two weeks.

(Source: GF Data LMM Report Q1 2026)

What the Market Is Telling Us This Week

• Supplement M&A is outperforming the broader consumer sector by design. Consumer M&A overall is down 34.7% year over year. Supplement deal volume is up. Health and wellness demand is holding in a way that discretionary categories are not. Brands with subscription or digital membership models are attracting the widest buyer set. (Source: Capstone Partners, June 2026)

• PE sponsors are back in the supplement market. Financial sponsor M&A hit 14 transactions YTD 2026 after a prior year slowdown. Private strategic buyers are up 30% year over year. Public acquirer activity is up 12.5% year over year. That combination of buyer types is what creates a competitive process, and a competitive process is what drives price above the sector average. (Source: Capstone Partners, June 2026)

• The sector multiple premium over broader consumer is holding. 10.7x supplement average versus 9.7x broader consumer. Brands with differentiated formulations and consumer loyalty are exiting at or above the sector average. Commodity supplement brands without those attributes are not. The market is sorting cleanly between the two. (Source: Capstone Partners Vitamins and Supplements M&A Update, 2025)

What This Means for Your Exit Timing

I built and sold a supplement company. I have also sold over a dozen supplement brands for clients since. The market I am looking at right now is one of the strongest windows I have seen for supplement exits since 2020.

Here is why that matters: when strategic buyers and PE sponsors are both active at the same time, in the same category, with overlapping target profiles, the competition between buyer types drives price in a way that a single acquirer conversation never will. Danone paying $1.2 billion for Huel is not the comparable that matters for a $5 million to $30 million supplement brand owner. What matters is that the same strategic logic driving that deal is also operating at the $5 million to $30 million level, and PE sponsors at 14 transactions YTD are offering an alternative that keeps every strategic buyer honest on price.

The window is open. The 10.7x sector average reflects that. Whether it stays open for six more months or eighteen months depends on macroeconomic factors no one can predict. What I can predict is that time is risk. I have watched supplement founders wait for a better moment that never came. I have also watched supplement founders who started a competitive process when the market looked like this walk away with 12x to 14x on clean businesses with strong formulations and consumer loyalty.

The three things that move your number from 8x to 12x in this market are: a subscription or loyalty model with verified retention data, a differentiated formulation story that strategic buyers cannot replicate cheaply, and a process that puts multiple buyer types in the room at the same time. None of those things happen without preparation that starts before you think you need it.

If you want to understand what your supplement brand would trade at in today's market, book a free valuation call. If you are earlier in the process and want to understand what buyers are underwriting, the ecommerce exit advisor page walks through the criteria in detail.

---

Frequently Asked Questions

What are supplement companies selling for in 2026?

The sector average multiple is 10.7x EV/EBITDA for 2024 through YTD 2025, according to Capstone Partners. That outperforms the broader consumer industry at 9.7x. The premium goes to brands with differentiated formulations, subscription or loyalty models, and demonstrated consumer retention. DTC brands with women's health positioning are commanding the highest premiums in the category right now. (Source: Capstone Partners Vitamins and Supplements M&A Update, June 2026)

What types of supplement brands are buyers targeting in 2026?

Three subsegments are drawing the heaviest buyer activity: women's health supplement brands, DTC brands with subscription or loyalty models, and supplement contract manufacturers (CDMOs). Strategic buyers dominate at 61% of deal volume YTD 2026, filling portfolio gaps with brands that have differentiated formulations and consumer loyalty. PE sponsors are targeting supplement CDMOs for scale through roll-up strategies. (Source: Capstone Partners Vitamins and Supplements M&A Report, June 2026; NutraIngredients Q1 2026)

Are PE buyers active in the supplement space?

Yes, and they are more active than they were twelve months ago. PE financial sponsor M&A in supplements has rebounded to 14 transactions YTD 2026. The Riverside Company acquiring Western Botanicals, a 140,000 square foot CDMO, is one example. PE is building platforms around contract manufacturing and personalized nutrition infrastructure, not just consumer brands. (Source: Capstone Partners Vitamins and Supplements M&A Report, June 2026)

What is driving supplement M&A while broader consumer deals are declining?

Consumer wellness demand is holding while discretionary spending in other categories has compressed. Supplement M&A is up year over year while the broader consumer sector fell 34.7% year over year. Brands that combine subscription or digital membership models with clean formulations are attracting CPG strategics and media or wellness buyers simultaneously. (Source: Capstone Partners Vitamins and Supplements M&A Report, June 2026)

What should a supplement brand owner do to position for a premium exit?

Three things separate a 10x outcome from a 7x outcome in this market. Own your customer relationship. Subscription models and loyalty data are what strategic buyers are paying a premium to acquire. Have a differentiated formulation story. Commodity supplement brands trade at a discount. Run a process with multiple competing buyers. Strategic buyers and PE sponsors are both active right now, and competition between buyer types is what drives price above the sector average. The window is open. Time is risk.